# A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

> **NCT05099133** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 24 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LEO 138559
- **DRUG:** LEO 138559 Placebo

## Key facts

- **NCT ID:** NCT05099133
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-03
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-06-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05099133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05099133, "A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05099133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*